Resona Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Resona Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Buy	21,192 +496	+2%	+$27.2K	0.01%	627
2026 Q1	$1.17M	Hold	20,696	–	–	0.01%	627
2025 Q4	$1.23M	Sell	20,696 -56,136	-73%	-$3.06M	0.01%	626
2025 Q3	$4.16M	Sell	76,832 -4,227	-5%	-$242K	0.02%	525
2025 Q2	$4.46M	Buy	81,059 +3,795	+5%	+$223K	0.02%	521
2025 Q1	$5.47M	Buy	77,264 +3,784	+5%	+$255K	0.03%	440
2024 Q4	$4.84M	Sell	73,480 -4,283	-6%	-$287K	0.03%	468
2024 Q3	$5.47M	Buy	77,763 +1,231	+2%	+$103K	0.03%	458
2024 Q2	$6.31M	Sell	76,532 -3,697	-5%	-$308K	0.04%	393
2024 Q1	$7.01M	Buy	+80,229	New	+$7.18M	0.04%	380

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Resona Asset Management's BMRN Position: Q2 2026 in Review

Resona Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 2.4% in Q2 2026, buying an estimated $27.2K and bringing the position to 21,192 shares worth $1.21M. The position accounts for 0.01% of the portfolio, ranked #627.

Resona Asset Management first reported a position in BMRN in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.01M in Q1 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Resona Asset Management held 21,192 shares of BioMarin Pharmaceuticals worth $1.21M as of Q2 2026.
Resona Asset Management bought 496 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $27.2K.
BioMarin Pharmaceuticals made up 0.01% of Resona Asset Management's portfolio in Q2 2026, its #627 holding.
Resona Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Resona Asset Management's BioMarin Pharmaceuticals position peaked at $7.01M in Q1 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Resona Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.